AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
